Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,433 |
Ending reported balance
After 2026-06-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-01 · Exercise / conversion · Acquired 639 · Balance 10,717 Row 2 · 2026-06-01 · Tax withholding · Disposed 284 · Balance 10,433 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Exercise / conversion · Disposed 639 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-26-000114 · wk-form4_1780434004.xml · derivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026. F2 · price: Not applicable. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 284 | $566.79 | $160,968.36 |
DisclosureSEC source: 0000874716-26-000114 · wk-form4_1780434004.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,433 Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 639 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000114 · wk-form4_1780434004.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 12 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612 Underlying: Common Stock · 204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 139 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 11 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278 Underlying: Common Stock · 139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 10 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56 Underlying: Common Stock · 56 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 55 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 9 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 199 | $629.35 | $125,240.65 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 5 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,078 F1 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 4 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 139 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 55 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 810 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 8 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 810 Underlying: Common Stock · 810 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 7 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,384 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 6 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,384 Underlying: Common Stock · 3,384 shares Expires 2036-02-11 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 11,345 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · derivative · entry 12 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,345 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Grant of option to buy 11,345 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2017. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 40 | $650.32 | $26,012.80 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 10 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,823 Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,809 | $649.26 | $1,823,771.06 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 9 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,863 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $649.05 to a high of $649.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 966 | $648.78 | $626,720.71 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 8 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,672 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $648.02 to a high of $649.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,060 | $647.21 | $686,039.00 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 7 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,638 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $646.825 to a high of $647.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,782 | $646.23 | $1,797,800.45 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 6 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,698 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $645.80 to a high of $646.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,161 | $645.25 | $1,394,387.84 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 5 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,480 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $644.75 to a high of $645.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 397 | $644.02 | $255,674.35 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 4 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,641 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $643.65 to a high of $644.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,130 | $643.00 | $726,587.06 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,038 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $642.595 to a high of $643.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 11,345 | $67.85 | $769,758.25 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,476 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · derivative · entry 11 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,476 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Grant of option to buy 1,476 shares of Issuer common stock that vested on February 14, 2021. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,476 | $67.85 | $100,146.60 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 12 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417 Underlying: Common Stock · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 11 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112 Underlying: Common Stock · 57 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2024. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2024. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 10 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55 Underlying: Common Stock · 56 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 51 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 9 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vested in four annual installments, beginning on February 14, 2022. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vested in four annual installments, beginning on February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vested in four annual installments, beginning on February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 133 | $444.53 | $59,122.49 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 5 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,347 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 4 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 51 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 816 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 8 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816 Underlying: Common Stock · 816 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 7 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:42 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,415 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 6 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,415 Underlying: Common Stock · 3,415 shares Expires 2035-02-12 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 9,986 | $0.00 Strike: $79.54 | $0.00 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · derivative · entry 5 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,986 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant of option to buy 9,986 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 9,986 | $462.53 | $4,618,861.53 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,176 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $462.4501 to a high of $462.80 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 9,986 | $79.54 | $794,286.44 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,256 | $0.00 Strike: $79.54 | $0.00 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · derivative · entry 4 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant of option to buy 628 shares of Issuer common stock that vested in one installment on February 14, 2020, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,256 | $79.54 | $99,902.24 |
DisclosureSEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 14 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169 Underlying: Common Stock · 57 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 13 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111 Underlying: Common Stock · 56 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning ion February 14, 2023. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning ion February 14, 2023. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning ion February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 52 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 12 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51 Underlying: Common Stock · 52 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 11 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 108 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 10 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in five annual installments beginning on February 14, 2020. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in five annual installments beginning on February 14, 2020. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in five annual installments beginning on February 14, 2020. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:55 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 557 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 9 FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557 Underlying: Common Stock · 557 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.